PTC Therapeutics Inc
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +10.5% | -26.8% | +45.4% | +185.8% | +45.1% | +36.0% | -12.2% | -12.0% | +11.1% | -10.1% | +70.0% | |
| – | +10.0% | -26.6% | -4.7% | +28.8% | +142.9% | +58.1% | -37.2% | -10.3% | +75.6% | +12.1% | +66.5% | |
| – | +7.5% | -31.6% | -17.4% | +19.0% | +26.6% | -27.5% | +270.4% | -63.8% | +112.3% | +31.3% | +26.3% | |
| – | +7.5% | -31.6% | -17.4% | +19.0% | +201.7% | +60.7% | -29.9% | -46.9% | +113.5% | +30.0% | +70.7% | |
| – | +149.6% | +124.7% | +62.0% | +68.1% | -18.2% | +25.9% | +58.0% | +40.9% | +3.3% | -1.4% | +14.5% | |
| – | – | – | +532.6% | +49.9% | +19.7% | -3.0% | -15.2% | +37.5% | +40.2% | -24.1% | +243.4% | |
| – | -2.0% | -17.2% | +12.7% | +51.6% | +69.8% | +57.0% | +284.3% | -44.2% | – | – | – | |
| – | – | – | – | -38.1% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | |
| – | – | – | – | +427.1% | +1.4% | +0.7% | +1.3% | -2.6% | -46.2% | -68.7% | +227.2% | |
| – | +100.2% | +115.3% | +57.1% | +226.7% | +34.0% | +67.7% | +12.2% | +6.0% | +32.2% | +3.3% | +10.7% | |
| – | +39.8% | +9.3% | +65.3% | +103.3% | +41.4% | +17.6% | +83.7% | -20.2% | +48.5% | -3.7% | +66.7% | |
| – | – | -55.5% | +49.6% | -80.9% | +115.6% | -65.2% | +1,728.3% | -47.1% | +148.8% | +28.9% | +115.8% | |
| – | +189.2% | -47.3% | +142.6% | -60.7% | +72.0% | +80.8% | +23.4% | +18.4% | -77.8% | +185.8% | +163.3% | |
| – | – | +3.8% | +47.6% | -2.5% | +107.9% | +5.2% | -8.8% | +102.8% | +233.0% | +10.8% | -4.0% | |
| – | +0.0% | -59.9% | +30.8% | +124.2% | +69.5% | -18.9% | -99.7% | -24,236.7% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +6.5% | +1.2% | +15.1% | +18.9% | +26.4% | +12.2% | +6.7% | +1.8% | +4.3% | +2.7% | +14.9% |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.